Equity Overview
Price & Market Data
Price: $8.50
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $49,151,344
Daily Volume: 0
Performance Metrics
1 Week: 3.22%
1 Month: 14.56%
3 Months: -10.24%
6 Months: -25.78%
1 Year: -9.77%
YTD: -5.16%
Company Details
Employees: 76
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.